Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Phase III Study Comparing Imatinib (STI571, Glivec®) Standard Dose (400 Mg/Day) With Imatinib High Dose Induction (800 Mg/Day) Followed by Standard Dose Maintenance (400 Mg/Day) in Pretreated CML Patients in Chronic Phase

NCT00327262 is registered in ClinicalTrials.gov with Central European Leukemia Study Group as lead sponsor.

NCT NCT00327262
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00327262 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Phase III Study Comparing Imatinib (STI571, Glivec®) Standard Dose (400 Mg/Day) With Imatinib High Dose Induction (800 Mg/Day) Followed by Standard Dose Maintenance (400 Mg/Day) in Pretreated CML Patients in Chronic Phase
Lead sponsor
Central European Leukemia Study Group
Phase
Phase 3
Overall status
Unknown status
Start date
January 31, 2004
Completion date
December 31, 2008
Enrollment
240
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloid leukemia